Search This Blog

Monday, March 23, 2026

Abivex results, cash, trial schedule

 

Abivax ADR beats Q4 2025 estimates with EPS -1.35, revenue $1.8M, ends year with €530.4M cash funding runway into Q4 2027

  • Non-GAAP EPS -1.35 improved 27% YoY in fiscal Q4 2025.
  • Q4 2025 revenue $1.8M declined 76% YoY from the prior year period.
  • Pivotal ABTECT-UC Phase 3 topline results remain on track for late Q2 2026.
  • March 18 DSMB review of ABTECT-UC Phase 3 maintenance trial found no new safety signals.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)